Oxygen Biotherapeutics, US Army ISR Sign Cooperative R&D Deal to Study Effects of Oxycyte on Ex Vivo Platelet Function
Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) at Fort Sam Houston Texas to explore the potential effects of OBI's proprietary perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis. This CRADA has been initiated to complement ongoing research and development work funded previously by a Department of Defense grant to broaden the safety profile of the use of perfluorocarbon-based emulsions to treat patients with traumatic brain injury – an indication for which OBI is conducting Phase II clinical trials overseas.
Although a known response to perfluorocarbon-based emulsion products is the transient decline in circulating platelet counts, the mechanism by which this phenomenon occurs is poorly understood and its impact on overall coagulation pathways and clinical outcomes remains the subject of debate. Recently completed in vitro studies using blood from normal healthy human volunteers at the Children's Hospital in Boston have demonstrated that Oxycyte has little effect on the activation and function of platelets. The research being conducted under the present CRADA will investigate whether Oxycyte alters platelet activation, aggregation or adhesion in a model of systemic inflammation. Researchers will conduct ex vivo evaluations of platelet activity and whole blood clotting functions. Changes in the structural and functional properties of platelets will be evaluated including receptor expression and distribution, and aggregation in response to agonists. This work will be part of a larger study to determine the biodistribution of platelets following Oxycyte administration in this model. The company has undertaken this extensive preclinical program to address concerns that the U.S. FDA has expressed regarding perfluorocarbon-based emulsions.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.